Q32 Bio (QTTB) Share-based Compensation (2017 - 2026)
Q32 Bio's quarterly Share-based Compensation came in at $1.5 million in Q1 2026, up 15.35% year-on-year from $1.3 million in Q1 2025, and up 5.38% quarter-over-quarter from $1.5 million in Q4 2025.
Q32 Bio has reported Share-based Compensation for 10 years, with the latest figure at $1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 15.35% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 2.82% YoY), and the FY2025 full-year result was $5.3 million, up 19.81% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.5 million, up from $1.5 million in the prior quarter.
- The five-year high for Share-based Compensation was $4.1 million in Q1 2022, with the low at $296000.0 in Q1 2023.
- Average Share-based Compensation over 5 years is $1.5 million, with a median of $1.3 million recorded in 2024.
- Year-over-year, Share-based Compensation tumbled 92.69% in 2023 and jumped 359.14% in 2024.
- Tracing QTTB's Share-based Compensation over 5 years: stood at $3.1 million in 2022, then sank by 83.13% to $521000.0 in 2023, then surged by 140.12% to $1.3 million in 2024, then climbed by 17.43% to $1.5 million in 2025, then climbed by 5.38% to $1.5 million in 2026.
- The last three Share-based Compensation figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.55 Mn |
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 417,000.00 |
| Mar 31, 2024 | 417,000.00 |
| Dec 31, 2023 | 521,000.00 |
| Dec 31, 2023 | 521,000.00 |
| Sep 30, 2023 | 301,000.00 |
| Sep 30, 2023 | 301,000.00 |
| Jun 30, 2023 | 310,000.00 |
| Jun 30, 2023 | 310,000.00 |
| Mar 31, 2023 | 296,000.00 |
| Mar 31, 2023 | 296,000.00 |
| Dec 31, 2022 | 3.09 Mn |
| Dec 31, 2022 | 3.09 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 4.05 Mn |
| Mar 31, 2022 | 4.05 Mn |
| Dec 31, 2021 | 4.66 Mn |
| Dec 31, 2021 | 4.66 Mn |
| Sep 30, 2021 | 4.23 Mn |
| Sep 30, 2021 | 4.23 Mn |
| Jun 30, 2021 | 4.47 Mn |
| Jun 30, 2021 | 4.47 Mn |
| Mar 31, 2021 | 3.88 Mn |
| Mar 31, 2021 | 3.88 Mn |
| Dec 31, 2020 | 3.57 Mn |
| Dec 31, 2020 | 3.57 Mn |
| Sep 30, 2020 | 3.35 Mn |
| Sep 30, 2020 | 3.35 Mn |
| Jun 30, 2020 | 3.45 Mn |
| Jun 30, 2020 | 3.45 Mn |
| Mar 31, 2020 | 2.88 Mn |
| Mar 31, 2020 | 2.88 Mn |
| Dec 31, 2019 | 2.44 Mn |
| Dec 31, 2019 | 2.44 Mn |
| Sep 30, 2019 | 1.99 Mn |
| Sep 30, 2019 | 1.99 Mn |
| Jun 30, 2019 | 1.97 Mn |
| Jun 30, 2019 | 1.97 Mn |
| Mar 31, 2019 | 1.24 Mn |
| Mar 31, 2019 | 1.24 Mn |
| Dec 31, 2018 | 955,000.00 |
| Dec 31, 2018 | 955,000.00 |
| Sep 30, 2018 | 719,000.00 |
| Sep 30, 2018 | 719,000.00 |
| Jun 30, 2018 | 569,000.00 |
| Jun 30, 2018 | 569,000.00 |
| Mar 31, 2018 | 380,000.00 |
| Mar 31, 2018 | 380,000.00 |
| Dec 31, 2017 | 160,858.00 |
| Dec 31, 2017 | 160,858.00 |
| Sep 30, 2017 | 57,884.00 |
| Sep 30, 2017 | 57,884.00 |
| Jun 30, 2017 | 30,578.00 |
| Jun 30, 2017 | 30,578.00 |
| Mar 31, 2017 | 27,680.00 |
| Mar 31, 2017 | 27,680.00 |